ImmuCell reports Q2 2026 results, expands capacity plans
ImmuCell reported second-quarter product sales of $7.2 million, net income of $1.8 million and gross margin of 33.9%, while planning $8 million in capacity investments.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.